12/24
07:01 pm
actu
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
12/23
04:09 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
07:02 pm
actu
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 [Yahoo! Finance]
Low
Report
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 [Yahoo! Finance]
12/18
08:45 am
actu
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
Low
Report
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
12/15
08:45 am
actu
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
High
Report
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
11/28
07:05 pm
actu
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% [Yahoo! Finance]
Medium
Report
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% [Yahoo! Finance]
11/26
02:00 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:07 am
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/15
07:05 pm
actu
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation [Yahoo! Finance]
11/14
01:10 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
02:37 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.